Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022091119 - A PHARMACEUTICAL KIT COMPRISING COPPER SULFATE AND ASCORBIC ACID

Publication Number WO/2022/091119
Publication Date 05.05.2022
International Application No. PCT/IN2021/051002
International Filing Date 22.10.2021
IPC
A61K 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Applicants
  • KUMAR, Gunjan [IN]/[IN]
  • KUMAR, Anurag [IN]/[IN]
  • VOLODYMYR STEPANOVYCH, Tarasenko [UA]/[UA]
  • DAVID ANATOLIIOVYCH, Noga [UA]/[UA]
  • YURIISERHIIOVYCH, Lysaichuk [UA]/[UA]
  • OLEKSANDR ANDRIIOVYCH, Tarasov [UA]/[UA]
Inventors
  • KUMAR, Gunjan
  • KUMAR, Anurag
  • VOLODYMYR STEPANOVYCH, Tarasenko
  • DAVID ANATOLIIOVYCH, Noga
  • YURIISERHIIOVYCH, Lysaichuk
  • OLEKSANDR ANDRIIOVYCH, Tarasov
Agents
  • MARAM, Suresh Gupta
Priority Data
20204104665126.10.2020IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) A PHARMACEUTICAL KIT COMPRISING COPPER SULFATE AND ASCORBIC ACID
(FR) KIT PHARMACEUTIQUE COMPRENANT DU SULFATE DE CUIVRE ET DE L'ACIDE ASCORBIQUE
Abstract
(EN) The present disclosure provides a pharmaceutical kit comprising oral liquid formulation of copper sulfate and oral solid formulation of ascorbic acid for treatment of coronavirus (COVID-19) disease. The pharmaceutical kit acts by preventing replication of viruses with envelopes in general and coronavirus in particular. Additionally, the disclosure provides a systematic method of administering the formulations of the pharmaceutical kit to prevent coronavirus replication/ infection in a subject in need thereof. Further, the disclosure also provides a process to prepare respective oral formulations of the pharmaceutical kit as disclosed in the present disclosure.
(FR) La présente invention concerne un kit pharmaceutique comprenant une formulation liquide orale de sulfate de cuivre et une formulation solide orale d'acide ascorbique pour le traitement d'une maladie à coronavirus (COVID-19). Le kit pharmaceutique agit en empêchant la réplication de virus à enveloppe en général et de coronavirus en particulier. De plus, l'invention concerne une méthode systématique d'administration des formulations du kit pharmaceutique pour empêcher la réplication/l'infection à coronavirus chez un sujet en ayant besoin. En outre, l'invention concerne également un procédé de préparation de formulations orales respectives du kit pharmaceutique selon la présente invention.
Latest bibliographic data on file with the International Bureau